Could AIM Become a New Option for Cats With Kidney Disease?

A new feline medicine is attracting attention in Japan because it targets one of the most serious health problems in older cats: chronic kidney disease (CKD). The product, now named FeliAIM, is based on research into a protein called AIM, or Apoptosis Inhibitor of Macrophages.

The research is promising. But the most accurate headline is not “a cure has arrived.” The evidence so far describes an exploratory study, ongoing development, and a regulatory application—not an approved or widely available treatment.

What is AIM?

AIM is a blood protein involved in the clearance of cellular waste. According to the Institute for AIM Medicine, its researchers have investigated how AIM may help the body remove waste that can contribute to disease. The institute has also proposed that cats’ vulnerability to kidney disease may be linked, in part, to impaired AIM activation.

This is a biological hypothesis with a potential therapeutic application. It is not a claim that every cat with kidney disease has the same underlying problem, or that AIM treatment will work for every patient.

What did the 2026 study report?

A study published in The Veterinary Journal examined the clinical impact of recombinant AIM in cats with advanced CKD. The researchers screened 216 cats. Thirty-five cats were enrolled based on the study’s criteria, including serum creatinine levels between 2.9 and 5.0 mg/dL.

Among the 26 cats with higher serum indoxyl sulfate levels, six received mouse recombinant AIM, five received feline recombinant AIM, and 15 served as untreated controls. Survival was monitored for 360 days, alongside kidney biomarkers, uremic toxins, metabolic profiles, and sphingolipids.

The untreated control group had a reported median survival time of 167 days. At 360 days, the reported cumulative survival was 0.83 for the mouse-AIM group and 0.80 for the feline-AIM group, compared with 0.20 in the untreated control group. The study also reported less worsening of some kidney biomarkers and uremic toxins in the treated groups.

These results provide a promising signal. They do not, by themselves, establish that AIM is a definitive treatment for feline CKD. The treatment groups were very small, and the study was described as exploratory and non-pivotal. The authors also reported a conflict of interest because some researchers owned stock in IAM CAT Inc.

Where does FeliAIM stand now?

The Institute for AIM Medicine announced that a clinical trial for the AIM cat medicine began at 26 veterinary hospitals in Japan in June 2025. On April 24, 2026, IAM CAT reported submitting an application to Japan’s Ministry of Agriculture, Forestry and Fisheries for manufacturing and marketing approval of FeliAIM as a veterinary medicine.

That distinction matters:

What has been reported	What it does not mean
Clinical development and a clinical trial in Japan	The product is approved everywhere
A Japanese application for manufacturing and marketing approval	Regulatory approval has already been granted
Encouraging findings from an exploratory study	The treatment is proven for every cat
The product name “FeliAIM”	The medicine is currently available to pet owners

Until the relevant regulator grants approval and the medicine is legally distributed, pet owners should not assume that FeliAIM is available or that a public release date is guaranteed.

What should cat parents do today?

CKD is common in older cats, and early veterinary monitoring remains important. Ask your veterinarian about an appropriate plan for your cat, which may include bloodwork, urinalysis, blood-pressure checks, hydration support, nutrition, and treatment of related problems. The right plan depends on the individual cat’s stage of disease, symptoms, laboratory results, and overall health.

Do not stop a prescribed treatment or give an experimental product based on social-media claims. Research updates can offer hope, but they should complement—not replace—veterinary care.

The bottom line

AIM research could become an important development in feline kidney medicine. The 2026 study reported encouraging outcomes in a small exploratory cohort, and FeliAIM has progressed to a Japanese regulatory application. The careful conclusion is that FeliAIM is promising and still under evaluation—not an approved cure that cat owners can already obtain.

At TwinTails.pet, we will keep following the evidence and separating confirmed facts from predictions, headlines, and wishful thinking.